Darren Feldman, MD (@DrDarrenFeldman), on ixotatug vedotin (TORL-1-23), a Claudin 6–targeted ADC, as monotherapy in germ cell tumours. #ESMO26 Watch now: bit.ly/3U0hG3M

Alfonso Gomez de Liano Lista, MD, on KEYNOTE-B15 quality of life: no difference between arms in MIBC; scores recovered after cystectomy in both arms, except sexual function. #ESMO26 Watch now: bit.ly/4ieoXGx

Manish Shah, MD, on the phase 3 KEYNOTE-975 study: pembrolizumab or placebo plus definitive chemoradiotherapy in esophageal and GEJ cancer. #ESMO26 Watch now: bit.ly/4Bnhlsu

Nilofer Azad, MD, FASCO, on COMPANION-002: paclitaxel ± tovecimig (anti-VEGF/DLL4 bispecific) in previously treated advanced biliary tract cancer. #ESMO26 Watch now: bit.ly/4BqfVO2

Andrew Redfern, MD, on CCTG MA.40/FINER: ipatasertib + fulvestrant kept its PFS benefit but did not improve OS in ER+/HER2− mBC after a CDK4/6 inhibitor. #ESMO26 Watch now: bit.ly/4skqDBu

Yukinori Ozaki, MD, PhD (@YukinoriOzaki), on JCOG1204A1: postoperative ctDNA surveillance, relapse-free survival and molecular lead time in high-risk breast cancer. #ESMO26 Watch now: oncologyeducation.com/videos…

Alessandra Gennari, MD, PhD: ER heterogeneity on 18F-FES PET vs. FDG-PET was linked to more than twice the risk of death on first-line endocrine therapy in ER+/HER2− mBC. #ESMO26 Watch now: bit.ly/4BrofNy

Gustavo Werutsky, MD, PhD (@GustavoWerutsky), on patient-reported outcomes from the phase 3 lidERA trial of adjuvant giredestrant in ER+/HER2− early breast cancer. #ESMO26 Watch now: bit.ly/4zMv1vx

FOURLIGHT-1 at #ESMO26: atirmociclib + fulvestrant improved PFS vs. investigator’s choice in HR+/HER2− mBC after a CDK4/6 inhibitor (median 9.4 vs. 6.6 mo; HR 0.60). Antonio Giordano, MD, PhD @antgiorda, explains Watch now: bit.ly/4zPpSD5

Sara Tolaney, MD, MPH @Sara on exploratory biomarker analyses from the phase 3 evERA trial of giredestrant + everolimus in ER+/HER2− advanced breast cancer after a CDK4/6 inhibitor. #ESMO26 Watch now: oncologyeducation.com/videos…

Oncology Education is in Madrid for #ESMO26! Follow along as our faculty experts share daily video vignettes on the key data from the congress.

In Canada, an estimated 8,800 women will be diagnosed with uterine cancer in 2026, making it the most common cancer of the female reproductive system in the country. Awareness matters & starts with education: bit.ly/4heYtme

Stay current on what’s changing in medical oncology. 🎧 @MedOncNow hosted by Dr. Shaqil Kassam, explores emerging therapies, evolving standards of care and practical insights with leading oncology experts. 🎧 Catch up on the latest episode now: bit.ly/4xCUhmB

Today is #CancerWellnessAwarenessDay. Wellness includes equitable access to cancer care. Explore practical strategies for delivering virtual cancer care with this free 30-minute CME (0.5 Mainpro+): bit.ly/4f9kiTx #VirtualCare #HealthEquity #CME

🚨 Schedule Update 🚨 ⏰ New Hours: 7:45 a.m.–3:00 p.m. EST Join us at #BestofASCO Toronto 2026 and enter for a chance to win Ray-Ban Meta Wayfarer Smart Glasses 🎁 📍 Draw: 12:55 p.m. #ASCO2026 #OncologyEducation

🎙️ New #MedOncNow Episode! Dr. Shaqil Kassam sits down with Dr. Howie Lim to discuss perioperative gastric cancer, emerging evidence, and evolving treatment strategies. Listen now. 🎧 #GastricCancer #Oncology #CancerCare #MedTwitter

🚨 Final day at #ASCO2026! This week we've seen advances in AI, blood-based biomarkers, immunotherapy, and precision oncology—all focused on delivering the right treatment to the right patient at the right time. Stay tuned for Day 4 highlights. 👇

🧬 @DrBetofMDPhD shares phase II results of OBX115, an engineered TIL therapy showing a 67% response rate in advanced melanoma, with a favorable safety profile and no need for systemic IL-2. bit.ly/4uPLFbQ #ASCO2026 #Melanoma

🧬 Dr. Paolo Ciracì presents an AI-powered histopathology biomarker that may help personalize upfront treatment decisions in metastatic colorectal cancer. bit.ly/4obI6dl

🎗️ Dr. Ghassan Abou-Alfa shares results from EMERALD-3, where adding STRIDE + TACE improved PFS to ~13 months versus 8–9 months with TACE alone in intermediate-stage HCC, supporting a potential new standard of care. bit.ly/4usskMV #ASCO2026